Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference;Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso

Medicina Clinica

Volumn 125, Issue 8, 2005, Pages 301-316

  Gisbert, Javier P ^a,e   Calvet, Xavier ^b   Gomollón, Fernando ^c   Monés, Joan ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Playa de Mojacar   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE;

CONFERENCE PAPER; ERADICATION THERAPY; HELICOBACTER PYLORI; SPAIN;

EID: 26844549131     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078424     Document Type: Conference Paper

References (80)

1. Sainz R, Borda F, Domínguez E, Gisbert JP. Conferencia Española de Consenso sobre la infección por Helicobacter pylori. Rev Esp Enferm Dig. 1999;91:777-84.
2. Gisbert JP, Calvet X, Gomollón F, Sainz R. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso. Med Clin (Barc). 2000;114:185-95.
3. Mascort JJ, Marzo M, Alonso-Coello P, Barenys M, Valdepérez J, Puigdengoles X, et al. Guía de práctica clínica sobre el manejo del paciente con dispepsia. Gastroenterol Hepatol. 2003;26:571-613.
4. Gisbert JP, Pajares JM, Valle J. Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review. Helicobacter. 1999;4:58-66.
5. Gisbert JP, Calvet X, González L, Pajares JM. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter. 2005; 10:157-71.
6. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-80.
7. Gisbert JP, Pajares JM. Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática. Med Clin (Barc). 2001;116:111-6.
8. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-84.
9. Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther. 1999;13:775-80.
10. Gomollón F, Santolaria S, Sicilia B, Ferrero M, Revillo MJ, Ducons J, et al. Resistencia de Helicobacter pylori al metronidazol y a la claritromicina: análisis descriptivo entre 1997 y 2000. Med Clin (Barc). 2004;123:481-5.
11. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:89-99.
12. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17:751-64.
13. Spencer CM, Faulds D. Esomeprazole. Drugs. 2000;60:321-9.
14. Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis. 2004;36:253-9.
15. Laine L. Review article: esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2002;16 Suppl 4:115-8.
16. Annibale B, D'Ambra G, Luzzi I, Marcheggiano A, Iannoni C, Paoletti M, et al. Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol. 1997;92:790-4.
17. Adamek RJ, Pfaffenbach B, Szymanski C. Pre-treatment with pantoprazole affect the efficacy of a modern triple therapy in H. pylori cure? Gut. 1997;41 Suppl 3:A211.
18. Bertoni G, Sassatelli R, Nigrisoli E, Tansini P, Bianchi G, Della Casa G, et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol. 1996;91:258-63.
19. Gisbert JP, Boixeda D, Martin de Argila C. Tratamiento previo con omeprazol y H. pylori ¿Disminuye la eficacia erradicadora de las «nuevas» terapias triples de una semana de duración? Med Clin (Barc). 1998;111:716.
20. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21:795-804.
21. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol. 1998;93:1080-4.
22. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949-58.
23. Higuchi K, Fujiwara Y, Tominaga K, Watanabe T, Shiba M, Nakamura S, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther. 2003;17:111-7.
24. Lai KC, Hui WM, Wong BC, Hu WH, Lam SK. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther. 2000;14:1071-6.
25. Calvet X, García N, López T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603-9.
26. Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol. 2001;13:1303-7.
27. Gisbert JP, Hermida C, Pajares JM. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? Hepatogastroenterology. 2001;48:1383-8.
28. De Boer WA, Tytgat GN. Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol. 2001;13:1281-4.
29. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven vs. ten-day of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial [en prensa]. Am J Gastroenterol. 2005.
30. Gisbert JP, Pajares JM. Helicobacter pylori test-and-treat' strategy for dyspeptic patients. Scand J Gastroenterol. 1999;34:644-52.
31. Calvet X, Gisbert JP. Estrategia test and treat en la infección por Helicobacter pylori. ¿Dónde, cuándo y a quién? Gastroenterología Práctica. 2005;17:4-12.
32. Gene E, Calvet X, Gisbert JP. Duración del tratamiento erradicador de Helicobacter pylori: siete o diez días. Estudio de coste efectividad [en prensa].
33. Gisbert JP, Pajares JM. Review article: Helicobacter pylori «rescue» regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047-57.
34. Gisbert JP, Pajares JM. Helicobacter pylori «rescue» regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047-57.
35. Gisbert JP, Pajares JM. Attitude facing a patient suffering from Helicobacter pylori infection resistant to a triple therapy. Rev Esp Enferm Dig. 2003;95:220-8, 210-19.
36. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther. 1999;13:163-8.
37. Zullo A, Hassan C, Campo SM, Lorenzetti R, Febbraro I, De Matthaeis M, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther. 2001;15:1193-7.
38. Gisbert JP, Fuentes J, Carpio D, Tito L, Guardiola J, Tomas A, et al. 7-day resum therapy with bismuth citrate after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2005;21:1249-53.
39. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day «rescue» therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther. 1999;13:1311-6.
40. Gisbert JP, Pajares JM. Helicobacter pylori «rescue» therapy after failure of two eradication treatments. A review [en prensa]. Helicobacter. 2005.
41. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:1333-43.
42. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. «Rescue» therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter. 2003;8:90-4.
43. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based «rescue therapy» for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther. 2000;14:311-6.
44. Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J Clin Gastroenterol. 2000;31:222-5.
45. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication «rescue therapy». Aliment Pharmacol Ther. 2001;15:143.
46. Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol. 2001;1:7.
47. Gisbert JP, Bujanda L, Calvet X, Gisbert JL, Marcos S, Olivares D, et al. Tratamiento de rescate con rifabutina tras múltiples fracasos erradicadores de H. pylori. Gastroenterol Hepatol. 2005;28:154.
48. Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis. 2001;19:134-43.
49. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003;18:627-33.
50. Zullo A, Hassan C, De Francesco V, Lorenzetti R, Marignani M, Angeletti S, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis. 2003;35:232-6.
51. Gisbert JP, Bermejo F, Ducons J, Pérez-Aisa A, Castro M, Benito LM, et al. Tratamiento de rescate con levofloxacino tras múltiples fracasos erradicadores de H. pylori. Gastroenterol Hepatol. 2005;28:153.
52. Xiao SD, Liu WZ, Hu PJ, Ouyang Q, Wang JL, Zhou LY, et al. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. Aliment Pharmacol Ther. 2001;15:81-6.
53. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple «rescue therapy» vs. quadruple «rescue therapy» for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther. 2002;16:1277-82.
54. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion. 2001;64:222-5.
55. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter. 2002;7:225-31.
56. Gisbert J, Khorrami S, Carballo F, Calvet X, Gene E, Domínguez- Muñoz J. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2003;4: CD004062.
57. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Domínguez-Muñoz E. Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther. 2004;19:617-29.
58. American Gastroenterological Association medical position statement. Evaluation of dyspepsia. Gastroenterology. 1998;114:579-81.
59. Hunt RH, Fallone CA, Thomson AB. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol. 1999;13:213-7.
60. North of England Dyspepsia Guideline Development Group. Dyspepsia: Managing dyspepsia in adults in primary care. [Revisado 13-9-2004.] Disponible en: http://www.nice.org.uk/pdf/CG01fullguides2004.
61. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003: CD001961.
62. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet. 2000;356:455-60.
63. Duggan AE, Elliott CA, Hawkey CJ, Logan RF. Does initial management of patients dyspepsia alter symptom response and patient satisfaction? Results from a randomised trial. Gastroenterology. 1999;116:A151.
64. Heaney A, Collins JS, Watson RG, McFarland RJ, Bamford KB, Tham TC. A prospective randomised trial of a «test and treat» policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut. 1999;45:186-90.
65. McColl KE, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia. BMJ. 2002;324:999-1002.
66. Arents NL, Thijs JC, van Zwet AA, Oudkerk Pool M, Gotz JM, van de Werf GT, et al. Approach to treatment of dyspepsia in primary care: a randomized trial comparing «test-and-treat» with prompt endoscopy. Arch Intern Med. 2003;163:1606-12.
67. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB. Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut. 2004;53:1758-63.
68. Farkkila M, Sarna S, Valtonen V, Sipponen P. Does the «test-and-treat» strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol. 2004;39:327-35.
69. Stevens R, Baxter G. Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care. Gastroenterology. 2001;120 Suppl 1:A50.
70. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ. 2002;324:1012-6.
71. Manes G, Menchise A, de Nucci C, Balzano A. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. BMJ. 2003;326:1118.
72. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol. 2003;98:2621-6.
73. Ladabaum U, Chey WD, Scheiman JM, Fendrick AM. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. Aliment Pharmacol Ther. 2002;16:1491-501.
74. Gisbert JP, Boixeda D, Martín de Argila C, García Plaza A. Helicobacter pylori y dispepsia no ulcerosa: una asignatura pendiente. Rev Esp Enferm Dig. 1998;90:441-53.
75. Gisbert JP. Diagnóstico de la infección por Helicobacter pylori. Rev Clin Esp. 2000;200:370-2.
76. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther. 2004;20:1001-17.
77. Marshall JK, Armstrong D, O'Brien BJ. Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis. Can J Gastroenterol. 2000;14:379-88.
78. Chey WD, Fendrick AM. Noninvasive Helicobacter pylori testing for the «test-and-treat» strategy: a decision analysis to assess the effect of past infection on test choice. Arch Intern Med. 2001;161:2129-32.
79. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter. 2004;9:347-68.
80. Gisbert JP, Badia X, Roset M, Pajares JM. The TETRA study: a prospective evaluation of Helicobacter pylori «test-and-treat» strategy on 736 patients in clinical practice. Helicobacter. 2004;9:28-38.